Power3 Medical Receives Additional Blood Samples to Continue Testing for Early Protein Indicators of Breast Cancer

THE WOODLANDS, Texas, Feb. 11, 2005 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces that the Mercy Women's Center has provided the Company with additional samples for the ongoing collaboration to test blood serum in order to identify and track protein biomarkers that are early indicators of breast cancer. Power3 Medical has completed testing of two previous large batches of samples as part of a research agreement which has made notable progress in the identification process of cancerous proteins.

Mercy Women's Center and Breast MRI of Oklahoma have been gathering blood samples from women undergoing MRI of the breast and have amassed the nation's largest collection of samples directly linked to MRI results. The Power3 Scientific Team believes that the larger the number of blood samples tested, the more accurate they can become in identifying specific protein biomarkers that are unique to women with breast cancer.

"The most recent group of serum samples contributed by Mercy Women's Center will allow our researchers to continue to refine and engineer a sensitive diagnostic test based on the specific protein biomarkers that they have identified as early indicators of cancer," according to Steven B. Rash, Power3 Medical Products' Chief Executive Officer. "Based on the encouraging results that have been achieved with the first two batches of serum samples, Power 3 is optimistic that this third group will help us achieve the next stage of our protein biomarker validation testing."

About Power3 Medical Products Inc.

Power3 Medical is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.


Contact Data